Glaxo Group Limited

Glaxosmithkline LLC

Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property Development Limited

The University of Edinburgh

University College Cardiff Consultants Limited

Kynos Therapeutics Limited

Ann Louise Walker

Paul Bamborough

Nicola Mary Aston

John Liddle

Richard Angell

George Cockerill

David Matthew Wilson

Stephen John Atkinson

Michael David Barker

Christopher Roland Wellaway

Robert John Sheppard

Matthew Campbell

Neil Stuart Garton

Clement Douault

Hawa Diallo

Mark James Bamford

Kathryn Jane Smith

Anne Marie Jeanne Bouillot

Alexis Denis

Stephen Sean Flack

Dramane Ibrahim Lainé

Suzanne Joy Merrick

Gerard Martin Paul Giblin

Stephen Swanson

Dominique Amans

Miles Stuart Congreve

Andrew McMurtrie Mason

Olivier Mirguet

Katherine Louise Jones

Neil Derek Miller

Susan Roomans

Jessica Fanny Renaux

Emmanuel Hubert Demont

Jonathan Thomas Seal

Vipulkumar Kantibhai Patel

Alan T Hudson

David Drysdale Miller

Ian Robert Baldwin

Sebastien Andre Campos

Paul Barraclough

Laddawan Chunchatprasert

Sadie Vile

Patrick Vivian Shannon

Timothy Longstaff

Anne-Marie Li-Kwai-Cheung

Pierre P Debont

Stephen Edward Shanahan

Haydn Terence Jones

Christopher Wellaway

Compounds of formula (I): wherein X, Y, Rand R-Rare as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. 

Benzoimidazole derivatives as PAD4 inhibitors

The present invention relates to methods and/or uses for treating pancreatitis, kidney diseases and other various disorders as described herein, for conditions or disorders mediated by KMO inhibitors, which comprises administering 6-chlorobenzoxazine compounds of Formula (I): orpharmaceutically acceptable salts and/or corresponding pharmaceutical compositions thereof.

Method of treating pancreatitis using 1,4-benzoxazine derivatives

The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

3-(6-alkoxy-5-chlorobenzo[D]isoxazol-3-YL)propanoic acid useful as kynurenine monooxygenase inhibitors

3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors

Compounds of formula (I) wherein; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl-O&#x2014;, or Calkoxy; Ris hydrogen, Calkyl, or CalkoxyCalkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl; or unsubstituted CcycloalkylCalkyl; A is C&#x2014;Ror N; B is C&#x2014;Ror N; D is C&#x2014;Ror N; with the proviso that at least one of A, B, and D, is N; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy, or hydroxy; Ris hydrogen or Calkyl, with the proviso that one of Rand Ris hydrogen; Ris hydrogen or hydroxy; Ris hydrogen or Calkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors

3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors

Compounds of formula (I) wherein; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl-O&#x2014;, or Calkoxy; Ris hydrogen, Calkyl, or CalkoxyCalkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl; or unsubstituted CcycloalkylCalkyl; A is C&#x2014;Ror N; B is C&#x2014;Ror N; D is C&#x2014;Ror N; with the proviso that at least one of A, B, and D, is N; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy, or hydroxy; Ris hydrogen or Calkyl, with the proviso that one of Rand Ris hydrogen; Ris hydrogen or hydroxy; Ris hydrogen or Calkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. 

2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors

Tetrahydroquinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.

Tetrahydroquinoline derivatives useful as bromodomain inhibitors

2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors

Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.

Nicotinamide derivates useful as P38 inhibitors

Nicotinamide derivatives useful as P38 inhibitors

Compounds of formula (I): or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors

Naphthalene derivatives

Growing community of inventors

Stevenage, United Kingdom

Ann Louise Walker